Large-scale analysis of cell cycle regulators in urothelial bladder cancer identifies p16 and p27 as potentially useful prognostic markers

Pathobiology

Volumn 75, Issue 1, 2008, Pages 25-33

  Brunner, Andrea ^a   Verdorfer, Irmgard ^a   Prelog, Martina ^b   Mayerl, Christina ^b   Mikuz, Gregor ^a   Tzankov, Alexandar ^c  

^a MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Bladder cancer; Cell cycle; Prognosis

Indexed keywords

CYCLIN D1; CYCLIN E; CYCLINE; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ARTICLE; BLADDER CANCER; CANCER SURVIVAL; CELL CYCLE REGULATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; UROTHELIUM;

CARCINOMA, TRANSITIONAL CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; IMMUNOENZYME TECHNIQUES; PROGNOSIS; ROC CURVE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 40549143398     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000113792     Document Type: Article

References (38)

1. Gillett CE, Barnes DM: Demystified ... cell cycle. Mol Pathol 1998;51:310-316.
2. Sgambato A, Migaldi M, Faraglia B, De Aloysio G, Ferrari P, Ardito R, De Gaetani C, Capelli G, Cittadini A, Trentini GP: Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome. Int J Cancer 2002;97:671-678.
3. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y: Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol 2006;37:1568-1576.
4. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Quintero A, Merlo F, Requena MJ, Montironi R: Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol 2004;122:444-452.
5. Tut VM, Braithwaite KL, Angus B, Neal DE, Lunec J, Mellon JK: Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. Br J Cancer 2001;84:270-275.
6. Yurakh AO, Ramos D, Calabuig-Farinas S, Lopez-Guerrero JA, Rubio J, Solsona E, Romanenko AM, Vozianov A, Pellin A, Llombart-Bosch A: Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol 2006;50:506-515.
7. Ong F, Moonen LM, Gallee MP, ten Bosch C, Zerp SF, Hart AAM, Bartelink H, Verheij M: Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53. Radiother Oncol 2001;61:169-175.
8. Mitra AP, Datar RH, Cote RJ: Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006;24:5552-5564.
9. ARF) gene in urinary bladder cancer using real-time quantitative PCR. Clin Cancer Res 2003;9:235-242.
10. Wagner U, Suess K, Luginbuhl T, Schmid U, Ackermann D, Zellweger T, Maurer R, Alund G, Knönagel H, Rist M, Jordan P, Moch H, Mihatsch MJ, Gasser TC, Sauter G: Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. J Pathol 1999;188:44-50.
11. Liukkonen T, Lipponen P, Raitanen M, Kaasinen E, Ala-Opas M, Rajala P, Kosma VM: Evaluation of p21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer. Finbladder Group. Urol Res 2000;28:285-292.
12. Kip1 and Ki-67 expression analysis in transitional cell carcinoma of the bladder. Urol Res 2003;31:397-401.
13. Doganay L, Altaner S, Bilgi S, Kaya E, Ekuklu G, Kutlu K: Expression of the cyclin-dependent kinase inhibitor p27 in transitional cell bladder cancers: is it a good predictor for tumor behavior? Int Urol Nephrol 2003;35:181-188.
14. Galmozzi F, Rubagotti A, Romagnoli A, Carmignani G, Perdelli L, Gatteschi B, Boccardo F: Prognostic value of cell cycle regulatory proteins in muscle-infiltrating bladder cancer. J Cancer Res Clin Oncol 2006;132:757-764.
15. Wu TT, Chen JH, Lee YH, Huang JK: The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 2000;163:758-760.
16. Santos LL, Amaro T, Pereira SA. Lameiras CR, Lopes P, Bento MJ, Oliveira J, Criado B, Lopes CS: Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Int J Cancer 2003;105:267-272.
17. Zlotta AR, Noel JC, Fayt I, Drowart A, Van Vooren JP, Huygen K, Simon J, Schulmann CC: Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guérin intravesical therapy. J Urol 1999;161:792-798.
18. Brunner A, Ensinger C, Christiansen M, Heiss S, Verdorfer I, Mikuz G, Tzankov A: Expression and prognostic significance of Tetranectin in invasive and non-invasive bladder cancer. Virchows Arch 2007;450:659-664.
19. Tzankov A, Went P, Zimpfer A, Dirnhofer S: Tissue microarray technology: principles, pitfalls and perspectives - lessons learned from hematological malignancies. Exp Gerontol 2005;40:737-744.
20. Hitchings AW, Kumar M, Jordan S, Nargund V, Martin J, Berney DM: Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb. Br J Cancer 2004;91:552-557.
21. KIP1 is abnormally expressed in diffuse large B-cell lymphomas and is associated with an adverse clinical outcome. Br J Cancer 1999;80:1427-1434.
22. Perkins NJ, Schisterman EF: The inconsistency of 'optimal' cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006;163:670-675.
23. Mhawech-Fauceglia P, Cheney RT, Schwaller J: Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer 2006;106:1205-1216.
24. Korkolopoulou P, Christodoulou P, Lazaris A, Thomas-Tsagli E, Kapralos P, Papanikolaou A, Kalliteraki P, Daveris P: Prognostic implications of aberrations in p16/pRb pathway in urothelial bladder carcinomas: a multivariate analysis including p53 expression and proliferation markers. Eur Urol 2001;39:167-177.
25. Kawamoto K, Enokide H, Gotande T, Kubo H, Nishiyama K, Kawahara M, Nakagawa M: p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Biochem Biophys Res Commun 2006;339:790-796.
26. Orlow I, Lacombe L, Hannon GJ, Serrano M, Pellicer I, Dalbagni G, Reuter VE, Zhang ZF, Beach D, Cordon-Cardo C: Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 1995;87:1524-1529.
27. Cairns P, Shaw ME, Knowles MA: Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 1993;8:1083-1085.
28. Kip1 and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer Br J Cancer 2001;84:1242-1251.
29. Zhang W, Bergamaschi D, Jin B, Lu X: Post-translational modifications of p27kip1 determine its binding specificity to different cyclins and cyclin-dependent kinases in vivo. Blood 2005;105:3691-3698.
30. Richter J, Wagner U, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knönagl H, Rist M, Wilber K, Anabitarte M, Hering F, Hardmeier T, Schönenberger A, Flury R, Jäger P, Fehr JL, Schraml P, Moch H, Mihatsch MJ, Gasser T, Kallioniemi OP, Sauter G: High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 2000;157:787-794.
31. Yoo J, Jung JH, Lee MA, Seo KJ, Shim BY, Kim SH, Cho DG, Ahn MI, Kim CH, Cho KD, Kang SJ, Kim HK: Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis. J Korean Med Sci 2007;22:318-325.
32. Kip1 and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst 2006;98:1723-1731.
33. Skalicky DA, Kench JG, Segara D, Coleman MJ, Sutherland RL, Henshall SM, Musgrove EA, Biankin AV: Cyclin E expression and outcome in pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2006;15:1941-1947.
34. Rosen DG, Yang G, Deavers MT, Malpica A, Kavanagh JJ, Mills GB, Liu J: Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer 2006;106:1925-1932.
35. Tzankov A, Gschwendtner A, Augustin F, Fiegl M, Obermann EC, Dirnhofer S, Went P: Diffuse large B-cell lymphoma with overexpression of cyclin E substantiates poor standard treatment response and inferior outcome. Clin Cancer Res 2006;12:2125-2132.
36. Vollmer RT, Humphrey PA, Swanson PE, Wick MR, Hudson ML: Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. Cancer 1998;82:715-723.
37. Amirghofran Z, Monabati A, Khezri A, Malek-Hosseini Z: Apoptosis in transitional cell carcinoma of bladder and its relation to proliferation and expression of p53 and bcl-2. Pathol Oncol Res 2004;10:154-158.
38. Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM: The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol 2003;169:1219-1228.